Engineered immune cells take on childhood cancer

NCT ID NCT06865664

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This early-phase trial tests a new treatment for children and young adults with rhabdomyosarcoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better target cancer cells. Up to 50 participants will receive the modified cells along with chemotherapy to prepare their bodies, and researchers will monitor safety and the right dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FGFR4-CAR T cells (a type of modified immune cell)
What this could lead to: If it works, this could point toward a new treatment option for children with hard-to-treat rhabdomyosarcoma.
What could go wrong: This is a very early Phase 1 trial with only 50 participants, so it may not work or could have serious side effects. The modified cells might not control the cancer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rhabdomyosarcoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHABDOMYOSARCOMA

Contacts and locations

Show contact details

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.